Lloyd E. Damon

7.3k total citations · 1 hit paper
110 papers, 3.8k citations indexed

About

Lloyd E. Damon is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Lloyd E. Damon has authored 110 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 38 papers in Oncology and 29 papers in Genetics. Recurrent topics in Lloyd E. Damon's work include Acute Myeloid Leukemia Research (32 papers), Acute Lymphoblastic Leukemia research (24 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Lloyd E. Damon is often cited by papers focused on Acute Myeloid Leukemia Research (32 papers), Acute Lymphoblastic Leukemia research (24 papers) and Chronic Lymphocytic Leukemia Research (18 papers). Lloyd E. Damon collaborates with scholars based in United States, Canada and United Kingdom. Lloyd E. Damon's co-authors include Charles Linker, James L. Rubenstein, Daniel J. DeAngelo, Michael McDermott, Curt A. Ries, Arthur Shen, Marc A. Shuman, Richard M. Stone, Tibor Kovacsovics and Wendy Stock and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lloyd E. Damon

108 papers receiving 3.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

2014 595 citations Lloyd E. Damon et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Lloyd E. Damon	1.5k	970	932	893	781	110	3.8k
G.J. Ossenkoppele	1.6k 1.0×	677 0.7×	1.1k 1.2×	812 0.9×	783 1.0×	84	3.3k
Martin Zimmermann	2.6k 1.7×	499 0.5×	1.1k 1.2×	950 1.1×	1.2k 1.5×	118	5.0k
Sanford Kempin	1.6k 1.1×	1.2k 1.2×	1.1k 1.2×	1.0k 1.1×	759 1.0×	69	3.9k
Minnie Abromowitch	1.1k 0.7×	558 0.6×	584 0.6×	838 0.9×	454 0.6×	67	3.0k
Michael Rytting	2.1k 1.4×	656 0.7×	1.3k 1.4×	414 0.5×	1.1k 1.4×	96	4.2k
David Lawrence	1.5k 1.0×	764 0.8×	614 0.7×	500 0.6×	1.1k 1.4×	73	3.3k
John Sweetenham	809 0.5×	1.5k 1.5×	2.0k 2.2×	2.8k 3.1×	551 0.7×	143	4.6k
Reinhard Stauder	2.7k 1.8×	1.4k 1.4×	976 1.0×	534 0.6×	1.4k 1.8×	122	4.9k
Dianne Pulte	1.4k 0.9×	569 0.6×	1.4k 1.5×	553 0.6×	1.0k 1.3×	87	3.5k
Uday Popat	4.0k 2.7×	1.5k 1.6×	1.9k 2.1×	973 1.1×	1.3k 1.7×	396	6.6k

Countries citing papers authored by Lloyd E. Damon

Since Specialization

Citations

This map shows the geographic impact of Lloyd E. Damon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lloyd E. Damon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lloyd E. Damon more than expected).

Fields of papers citing papers by Lloyd E. Damon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lloyd E. Damon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lloyd E. Damon. The network helps show where Lloyd E. Damon may publish in the future.

Co-authorship network of co-authors of Lloyd E. Damon

This figure shows the co-authorship network connecting the top 25 collaborators of Lloyd E. Damon. A scholar is included among the top collaborators of Lloyd E. Damon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lloyd E. Damon. Lloyd E. Damon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jonas, Brian A., Peter Curtin, Gary J. Schiller, et al.. (2025). A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. 155. 107717–107717.

Lo, Mimi, et al.. (2023). Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients. Bone Marrow Transplantation. 58(11). 1247–1253. 2 indexed citations

Huang, Li‐Wen, Ying Sheng, Charalambos Andreadis, et al.. (2022). Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplantation and Cellular Therapy. 28(6). 309.e1–309.e9. 3 indexed citations

Ali, Mir, et al.. (2020). Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review. SHILAP Revista de lepidopterología. 2020. 1–6. 8 indexed citations

Sheng, Ying, Chiung‐Yu Huang, Charalambos Andreadis, et al.. (2020). Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. Journal of Geriatric Oncology. 12(4). 531–539. 4 indexed citations

Ko, Andrew H., Alexander C. Jordan, Simon F. Lacey, et al.. (2020). Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular Therapy. 28(11). 2367–2378. 42 indexed citations

Schwartz, Marc S., Lloyd E. Damon, Deepa Jeyakumar, et al.. (2019). Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504. Blood. 134(Supplement_1). 3880–3880. 10 indexed citations

Schiller, Gary J., et al.. (2018). High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial. Journal of Adolescent and Young Adult Oncology. 7(5). 546–552. 22 indexed citations

Wieduwilt, Matthew J., Brian A. Jonas, Gary J. Schiller, et al.. (2018). A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood. 132(Supplement 1). 4018–4018. 5 indexed citations

10.

Mulè, Matthew P., Gabriel N. Mannis, Brent L. Wood, et al.. (2016). Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(11). 1974–1982. 20 indexed citations

11.

Keller, Jesse W., Charalambos Andreadis, Lloyd E. Damon, et al.. (2014). Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. Journal of Geriatric Oncology. 5(3). 238–244. 10 indexed citations

12.

Wieduwilt, Matthew J., Francisco Valles, Samar Issa, et al.. (2012). Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI. Clinical Cancer Research. 18(4). 1146–1155. 99 indexed citations

13.

Loon, Katherine Van, Ryan M. Gill, Patrick J. McMahon, et al.. (2012). 20q– Clonality in a Case of Oral Sweet Syndrome and Myelodysplasia. American Journal of Clinical Pathology. 137(2). 310–315. 14 indexed citations

14.

O’Donnell, Margaret, Jessica K. Altman, Frederick R. Appelbaum, et al.. (2011). Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network. 9(3). 280–317. 53 indexed citations

15.

Martin, Thomas, Lloyd E. Damon, Lawrence Kaplan, et al.. (2009). Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease. 12(1). 45–50. 18 indexed citations

16.

Hsi, Eric D., Sin‐Ho Jung, Raymond Lai, et al.. (2008). Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leukemia & lymphoma. 49(11). 2081–2090. 87 indexed citations

17.

Rubenstein, James L., Jane Fridlyand, Lauren E. Abrey, et al.. (2007). Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma. Journal of Clinical Oncology. 25(11). 1350–1356. 243 indexed citations

18.

Michaels, Marian G., Christina L. Kaufman, Paul A. Volberding, et al.. (2004). Baboon Bone-Marrow Xenotransplant in a Patient with Advanced HIV Disease: Case Report and 8-Year Follow-Up. Transplantation. 78(11). 1582–1589. 10 indexed citations

19.

Kröger, Nicolaus, Lloyd E. Damon, A R Zander, et al.. (2003). Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplantation. 32(12). 1153–1157. 56 indexed citations

20.

Seiter, Karen, Lloyd E. Damon, Claudia Linker, et al.. (1997). A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia. 11(4). 485–489. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact